Company / Return on Equity (ROE)
Annovis Bio, Inc. Return on Equity (ROE) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-171.2%
FY2025
5-year range
-171.2% / -72.4%
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Annovis Bio, Inc. reports negative total equity of -171.2% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-171.2% in FY2025 with a 3-year CAGR of -81.8%.
Declined from -89.4% to -171.2% over the past 3 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -81.8pp
- 5-Year Change
- -
- 10-Year Change
- -
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.28 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -171.2% | - |
| FY2024 | - | - |
| FY2023 | -89.4% | +0.0% |
| FY2022 | -89.4% | -23.5% |
| FY2021 | -72.4% | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026